Acute Respiratory Distress SyndromeHemodyCACCNCT06699017
Effect of Continuous Anterior Chest Compression on Ventilation/Perfusion Ratio and Hemodynamics
A study testing Continuous anterior chest compression in people with Acute Respiratory Distress Syndrome, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Intro: The mortality of acute respiratory distress syndrome (ARDS) remains high (40%), and may be aggravated by ventilation-induced lung injury (VILI), the main mechanisms of which are: 1. Anterior region overdistension, 2. Atelectrauma in the posterior regions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Respiratory Distress Syndrome
- What is being tested?
- Continuous anterior chest compression
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 28 Feb 2023to 30 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- ARDS moderate to severe according to the Berlin criteria
- Patient receiving continuous sedation and curarization
- Free and informed consent from the patient or family member
Who cannot join
- Pregnancy
- Adult patient subject to a legal protection measure (tutor, curator, etc.)
- Patients with a pacemaker, automatic implantable cardioverter defibrillator,
- Contraindications to thoracic belt placement (e.g., thoracic or spinal cord trauma, recent thoracic surgery)
- Undrained pneumothorax, bronchopleural fistula
- Hemodynamic instability (i.e., use of intravenous fluids of more than 10 mL/kg or vasopressors 2 mg/h of norepinephrine or 0.5 mg/h of epinephrine)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Effects of Continuous Anterior Chest Compression on Ventilation/Perfusion Ratios and Hemodynamics in SDRA
Intro:
The mortality of acute respiratory distress syndrome (ARDS) remains high (40%), and may be aggravated by ventilation-induced lung injury (VILI), the main mechanisms of which are:
Read more
- Anterior region overdistension,
- Atelectrauma in the posterior regions. Positive expiratory pressure (PEEP) adjusted on the ventilator during ARDS aims to recruit posterior pulmonary territories in order to limit atelectrauma but is accompanied by a concomitant risk of overdistension of anterior territories.
Recent data suggest that continuous anterior chest compression (CACC) could limit the overdistension of the anterior regions by decreasing the compliance of the anterior chest wall and thus the regional transpulmonary pressure, while promoting the redistribution of ventilation to the posterior territories.
The effects of CCAC on ventilation/perfusion ratios and hemodynamics are unknown.
Hypothesis/Objective :
The participants hypothesize that during ARDS, CCAC:
- Improves ventilation/perfusion ratios by decreasing both anterior territory dead space effect and posterior territory shunt,
- Induce an improvement in cardiac output by decreasing right ventricular afterload (decrease in capillary compression related to the overdistension of the anterior territories and decrease in hypoxic vasoconstriction of the condensed territories).
Objective:
Primary outcome :
To evaluate the effects of CCAC on ventilation/perfusion ratios during moderate to severe ARDS.
Secondary outcome :
To evaluate the effects of CCAC on hemodynamics : left heart morphology, systolic and diastolic function, cardiac output, right heart morphology, systolic function, pulmonary hypertension, volemia.
Method In patient with moderate to severe ARDS, CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
Electrical impedance tomography of ventilation and perfusion will be used for the measurement of the percentage of areas with normal VA/Q ratios, areas of shunt and areas of dead space effect.
Left heart morphology, systolic and diastolic function, cardiac output, right heart morphology, systolic function, pulmonary hypertension, volemia will be evaluated by using echocardiography.
- Conditions
- Acute Respiratory Distress Syndrome
- Being tested
- Continuous anterior chest compression
- Keywords
- ARDS, cardiac output, ventilation perfusion ratio
- Medical subject headings
- Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous anterior chest compressionOther
CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
| Study group | Role | What they receive |
|---|---|---|
| Patient with moderate to severe ARDS under sedation andcontinuous curarization | Experimental | Patient with moderate to severe ARDS under sedation andcontinuous curarization Receives: Other: Continuous anterior chest compression |
What is being measured
The primary outcome is the main question the study is designed to answer.
percentage of areas with normal VA/Q ratios, areas of shunt and areas of dead space effect.
demonstration that CACC may improve VA/Q ratio by using electrical impedance tomography
Measured: 28 days
Secondary outcomes (6)
CACC may induce a modification in cardiac output by decreasing right ventricular afterload
measurement of cardiac output with echocardiography via : left ventricle outflow tract velocity time integral cm)
Measured: 28 days
CACC may induce a modification in patient with right ventricular injury
RV/LV : right ventricle end-diastolic ratio, to LV end-diastolic diameter ratio, sLV eccentricity index : systolic left ventricle eccentricity index; ACP : Acute cor pulmonale
Measured: 28 days
CACC may induce a modification in right systolic function
measurement of right systolic function paramaters : TAPSE (mm) , S' annular tricuspid wave (m/s), RVFAC (%)
Measured: 28 days
CACC may induce a modification in left systolic function
LVEF : left ventricular ejection fraction
Measured: 28 days
CACC may induce a modification in ventilation distribution
ventilation distribution antero-posterior and right/left, assessed by electrical impedance tomography
Measured: 28 days
CACC may induce a modification in lung perfusion distribution
lung perfusion distribution antero-posterior and right/left assessed by electrical impedance tomography
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2024
- Study start28 Feb 2023
- Primary completion30 Jun 2024
- Study completion30 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Respiratory Distress SyndromeStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Patient with moderate to severe ARDS under sedation and curarization keep on going
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06699017
- Sponsor's protocol ID
- APHP230065
- Acronym
- HemodyCACC
- Status last verified
- Jan 2026
- First submitted
- 28 Feb 2023
- Last updated
- 15 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effects of Continuous Anterior Chest Compression on Ventilation/Perfusion Ratios and Hemodynamics in SDRA
- ClinicalTrials.gov ID
- NCT06699017
- Acronym / sponsor ID
- HemodyCACC / APHP230065
- Conditions
- Acute Respiratory Distress Syndrome
- Keywords
- ARDS, cardiac output, ventilation perfusion ratio
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 28 Feb 2023 (actual)
- Primary completion
- 30 Jun 2024 (actual)
- Study completion
- 30 Jun 2024 (actual)
- First posted
- 21 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intro:
The mortality of acute respiratory distress syndrome (ARDS) remains high (40%), and may be aggravated by ventilation-induced lung injury (VILI), the main mechanisms of which are:
- Anterior region overdistension,
- Atelectrauma in the posterior regions. Positive expiratory pressure (PEEP) adjusted on the ventilator during ARDS aims to recruit posterior pulmonary territories in order to limit atelectrauma but is accompanied by a concomitant risk of overdistension of anterior territories.
Recent data suggest that continuous anterior chest compression (CACC) could limit the overdistension of the anterior regions by decreasing the compliance of the anterior chest wall and thus the regional transpulmonary pressure, while promoting the redistribution of ventilation to the posterior territories.
The effects of CCAC on ventilation/perfusion ratios and hemodynamics are unknown.
Hypothesis/Objective :
The participants hypothesize that during ARDS, CCAC:
- Improves ventilation/perfusion ratios by decreasing both anterior territory dead space effect and posterior territory shunt,
- Induce an improvement in cardiac output by decreasing right ventricular afterload (decrease in capillary compression related to the overdistension of the anterior territories and decrease in hypoxic vasoconstriction of the condensed territories).
Objective:
Primary outcome :
To evaluate the effects of CCAC on ventilation/perfusion ratios during moderate to severe ARDS.
Secondary outcome :
To evaluate the effects of CCAC on hemodynamics : left heart morphology, systolic and diastolic function, cardiac output, right heart morphology, systolic function, pulmonary hypertension, volemia.
Method In patient with moderate to severe ARDS, CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
Electrical impedance tomography of ventilation and perfusion will be used for the measurement of the percentage of areas with normal VA/Q ratios, areas of shunt and areas of dead space effect.
Left heart morphology, systolic and diastolic function, cardiac output, right heart morphology, systolic function, pulmonary hypertension, volemia will be evaluated by using echocardiography.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Patient with moderate to severe ARDS under sedation and curarization keep on going
| Arm | Type | Receives |
|---|---|---|
| Patient with moderate to severe ARDS under sedation andcontinuous curarization | Experimental | Other: Continuous anterior chest compressionPatient with moderate to severe ARDS under sedation andcontinuous curarization |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- ARDS moderate to severe according to the Berlin criteria
- Patient receiving continuous sedation and curarization
- Free and informed consent from the patient or family member
Key exclusion criteria (6 listed)
- Pregnancy
- Adult patient subject to a legal protection measure (tutor, curator, etc.)
- Patients with a pacemaker, automatic implantable cardioverter defibrillator,
- Contraindications to thoracic belt placement (e.g., thoracic or spinal cord trauma, recent thoracic surgery)
- Undrained pneumothorax, bronchopleural fistula
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous anterior chest compressionCACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O. | Other | Patient with moderate to severe ARDS under sedation andcontinuous curarization |
Primary outcome
percentage of areas with normal VA/Q ratios, areas of shunt and areas of dead space effect.
Time frame: 28 days
demonstration that CACC may improve VA/Q ratio by using electrical impedance tomography
6 secondary outcomes
CACC may induce a modification in cardiac output by decreasing right ventricular afterload
Time frame: 28 days
CACC may induce a modification in patient with right ventricular injury
Time frame: 28 days
CACC may induce a modification in right systolic function
Time frame: 28 days
CACC may induce a modification in left systolic function
Time frame: 28 days
CACC may induce a modification in ventilation distribution
Time frame: 28 days
CACC may induce a modification in lung perfusion distribution
Time frame: 28 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Individual participant dataSharing planned: No. DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
Related trials for Acute Respiratory Distress Syndrome
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
RecruitingObservational study
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ARDS
Recruiting
Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants
Surfactant, Respiratory Distress Syndrome (Neonatal)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous anterior chest compression in people with Acute Respiratory Distress Syndrome, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
percentage of areas with normal VA/Q ratios, areas of shunt and areas of dead space effect. (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.